nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—FGFR2—stomach cancer	0.4	1	CbGaD
Ponatinib—ABCB1—Mitomycin—stomach cancer	0.0329	0.148	CbGbCtD
Ponatinib—ABCB11—Doxorubicin—stomach cancer	0.0269	0.121	CbGbCtD
Ponatinib—ABCG2—Irinotecan—stomach cancer	0.0234	0.105	CbGbCtD
Ponatinib—ABCG2—Fluorouracil—stomach cancer	0.0225	0.101	CbGbCtD
Ponatinib—ABCG2—Docetaxel—stomach cancer	0.0171	0.0773	CbGbCtD
Ponatinib—CYP3A5—Irinotecan—stomach cancer	0.013	0.0584	CbGbCtD
Ponatinib—ABCG2—Doxorubicin—stomach cancer	0.0128	0.0576	CbGbCtD
Ponatinib—ABCG2—Methotrexate—stomach cancer	0.0124	0.0558	CbGbCtD
Ponatinib—CYP2C8—Fluorouracil—stomach cancer	0.012	0.0539	CbGbCtD
Ponatinib—CYP3A5—Docetaxel—stomach cancer	0.0095	0.0428	CbGbCtD
Ponatinib—ABCB1—Irinotecan—stomach cancer	0.00844	0.038	CbGbCtD
Ponatinib—ABCB1—Docetaxel—stomach cancer	0.00618	0.0279	CbGbCtD
Ponatinib—ABCB11—bile—stomach cancer	0.00531	0.068	CbGeAlD
Ponatinib—KIT—myenteric nerve plexus—stomach cancer	0.00518	0.0663	CbGeAlD
Ponatinib—CYP3A4—Irinotecan—stomach cancer	0.00505	0.0228	CbGbCtD
Ponatinib—ABCB1—Doxorubicin—stomach cancer	0.00461	0.0208	CbGbCtD
Ponatinib—ABCB1—Methotrexate—stomach cancer	0.00446	0.0201	CbGbCtD
Ponatinib—CYP2D6—Doxorubicin—stomach cancer	0.00434	0.0196	CbGbCtD
Ponatinib—CYP3A4—Docetaxel—stomach cancer	0.0037	0.0167	CbGbCtD
Ponatinib—CYP3A4—Doxorubicin—stomach cancer	0.00276	0.0124	CbGbCtD
Ponatinib—FGFR4—hematopoietic system—stomach cancer	0.00182	0.0233	CbGeAlD
Ponatinib—Nilotinib—MAPK8—stomach cancer	0.00167	0.388	CrCbGaD
Ponatinib—TEK—blood vessel—stomach cancer	0.00146	0.0187	CbGeAlD
Ponatinib—SRC—blood vessel—stomach cancer	0.0013	0.0166	CbGeAlD
Ponatinib—FGFR4—digestive system—stomach cancer	0.00126	0.0162	CbGeAlD
Ponatinib—LYN—hematopoietic system—stomach cancer	0.00125	0.016	CbGeAlD
Ponatinib—PDGFRA—gall bladder—stomach cancer	0.00125	0.0159	CbGeAlD
Ponatinib—FGFR3—hematopoietic system—stomach cancer	0.00124	0.0159	CbGeAlD
Ponatinib—KDR—blood vessel—stomach cancer	0.00119	0.0153	CbGeAlD
Ponatinib—ABL1—Topotecan—Irinotecan—stomach cancer	0.00119	0.424	CbGdCrCtD
Ponatinib—FGFR3—epithelium—stomach cancer	0.00113	0.0145	CbGeAlD
Ponatinib—BCR—hematopoietic system—stomach cancer	0.00107	0.0137	CbGeAlD
Ponatinib—FLT3—hematopoietic system—stomach cancer	0.00107	0.0136	CbGeAlD
Ponatinib—KIT—blood vessel—stomach cancer	0.00106	0.0135	CbGeAlD
Ponatinib—FGFR4—endocrine gland—stomach cancer	0.00104	0.0134	CbGeAlD
Ponatinib—KIT—gall bladder—stomach cancer	0.000996	0.0127	CbGeAlD
Ponatinib—FGFR4—liver—stomach cancer	0.000942	0.0121	CbGeAlD
Ponatinib—LYN—lymphoid tissue—stomach cancer	0.000878	0.0112	CbGeAlD
Ponatinib—RET—hematopoietic system—stomach cancer	0.000855	0.0109	CbGeAlD
Ponatinib—FGFR2—hematopoietic system—stomach cancer	0.000812	0.0104	CbGeAlD
Ponatinib—RET—epithelium—stomach cancer	0.000781	0.00999	CbGeAlD
Ponatinib—TEK—hematopoietic system—stomach cancer	0.000778	0.00996	CbGeAlD
Ponatinib—Nilotinib—CA1—stomach cancer	0.000777	0.18	CrCbGaD
Ponatinib—BCR—lymphoid tissue—stomach cancer	0.000756	0.00967	CbGeAlD
Ponatinib—FLT3—lymphoid tissue—stomach cancer	0.00075	0.0096	CbGeAlD
Ponatinib—FGFR2—epithelium—stomach cancer	0.000742	0.0095	CbGeAlD
Ponatinib—FGFR4—lymph node—stomach cancer	0.000722	0.00924	CbGeAlD
Ponatinib—LYN—endocrine gland—stomach cancer	0.000716	0.00917	CbGeAlD
Ponatinib—FGFR2—smooth muscle tissue—stomach cancer	0.000715	0.00915	CbGeAlD
Ponatinib—FGFR3—endocrine gland—stomach cancer	0.000713	0.00912	CbGeAlD
Ponatinib—TEK—epithelium—stomach cancer	0.000712	0.0091	CbGeAlD
Ponatinib—PDGFRA—hematopoietic system—stomach cancer	0.000705	0.00902	CbGeAlD
Ponatinib—SRC—hematopoietic system—stomach cancer	0.000692	0.00885	CbGeAlD
Ponatinib—BCR—bone marrow—stomach cancer	0.000688	0.0088	CbGeAlD
Ponatinib—TEK—smooth muscle tissue—stomach cancer	0.000686	0.00877	CbGeAlD
Ponatinib—FLT3—bone marrow—stomach cancer	0.000683	0.00874	CbGeAlD
Ponatinib—Imatinib—CA1—stomach cancer	0.000648	0.15	CrCbGaD
Ponatinib—LYN—liver—stomach cancer	0.000646	0.00827	CbGeAlD
Ponatinib—FGFR3—liver—stomach cancer	0.000643	0.00822	CbGeAlD
Ponatinib—KDR—hematopoietic system—stomach cancer	0.000636	0.00814	CbGeAlD
Ponatinib—TEK—pancreas—stomach cancer	0.000634	0.00811	CbGeAlD
Ponatinib—SRC—epithelium—stomach cancer	0.000632	0.00809	CbGeAlD
Ponatinib—PDGFRA—smooth muscle tissue—stomach cancer	0.000621	0.00795	CbGeAlD
Ponatinib—BCR—endocrine gland—stomach cancer	0.000617	0.00789	CbGeAlD
Ponatinib—FLT3—endocrine gland—stomach cancer	0.000612	0.00784	CbGeAlD
Ponatinib—SRC—smooth muscle tissue—stomach cancer	0.000609	0.00779	CbGeAlD
Ponatinib—RET—lymphoid tissue—stomach cancer	0.000602	0.0077	CbGeAlD
Ponatinib—RET—digestive system—stomach cancer	0.000594	0.0076	CbGeAlD
Ponatinib—Nilotinib—CA2—stomach cancer	0.000589	0.136	CrCbGaD
Ponatinib—KDR—epithelium—stomach cancer	0.000582	0.00744	CbGeAlD
Ponatinib—ABCB11—digestive system—stomach cancer	0.00058	0.00743	CbGeAlD
Ponatinib—FGFR2—digestive system—stomach cancer	0.000565	0.00722	CbGeAlD
Ponatinib—KIT—hematopoietic system—stomach cancer	0.000564	0.00721	CbGeAlD
Ponatinib—SRC—pancreas—stomach cancer	0.000563	0.00721	CbGeAlD
Ponatinib—KDR—smooth muscle tissue—stomach cancer	0.00056	0.00717	CbGeAlD
Ponatinib—BCR—liver—stomach cancer	0.000556	0.00711	CbGeAlD
Ponatinib—FLT3—liver—stomach cancer	0.000552	0.00706	CbGeAlD
Ponatinib—TEK—lymphoid tissue—stomach cancer	0.000548	0.00701	CbGeAlD
Ponatinib—LCK—bone marrow—stomach cancer	0.000548	0.00701	CbGeAlD
Ponatinib—KIT—epithelium—stomach cancer	0.000515	0.00659	CbGeAlD
Ponatinib—KIT—smooth muscle tissue—stomach cancer	0.000497	0.00635	CbGeAlD
Ponatinib—PDGFRA—lymphoid tissue—stomach cancer	0.000497	0.00635	CbGeAlD
Ponatinib—FGFR1—liver—stomach cancer	0.000495	0.00633	CbGeAlD
Ponatinib—Imatinib—CA2—stomach cancer	0.000491	0.114	CrCbGaD
Ponatinib—RET—endocrine gland—stomach cancer	0.000491	0.00628	CbGeAlD
Ponatinib—ABL1—hematopoietic system—stomach cancer	0.000491	0.00628	CbGeAlD
Ponatinib—PDGFRA—digestive system—stomach cancer	0.00049	0.00628	CbGeAlD
Ponatinib—SRC—lymphoid tissue—stomach cancer	0.000487	0.00623	CbGeAlD
Ponatinib—SRC—digestive system—stomach cancer	0.000481	0.00615	CbGeAlD
Ponatinib—ABCB11—endocrine gland—stomach cancer	0.00048	0.00614	CbGeAlD
Ponatinib—FGFR2—endocrine gland—stomach cancer	0.000467	0.00597	CbGeAlD
Ponatinib—KIT—pancreas—stomach cancer	0.000459	0.00587	CbGeAlD
Ponatinib—KDR—lymphoid tissue—stomach cancer	0.000448	0.00573	CbGeAlD
Ponatinib—TEK—endocrine gland—stomach cancer	0.000447	0.00572	CbGeAlD
Ponatinib—LCK—liver—stomach cancer	0.000443	0.00566	CbGeAlD
Ponatinib—KDR—digestive system—stomach cancer	0.000442	0.00566	CbGeAlD
Ponatinib—ABCB11—liver—stomach cancer	0.000432	0.00553	CbGeAlD
Ponatinib—ABL1—smooth muscle tissue—stomach cancer	0.000432	0.00553	CbGeAlD
Ponatinib—BCR—lymph node—stomach cancer	0.000426	0.00545	CbGeAlD
Ponatinib—FLT3—lymph node—stomach cancer	0.000423	0.00542	CbGeAlD
Ponatinib—FGFR2—liver—stomach cancer	0.000421	0.00538	CbGeAlD
Ponatinib—KDR—bone marrow—stomach cancer	0.000408	0.00522	CbGeAlD
Ponatinib—PDGFRA—endocrine gland—stomach cancer	0.000405	0.00519	CbGeAlD
Ponatinib—TEK—liver—stomach cancer	0.000403	0.00516	CbGeAlD
Ponatinib—ABL1—pancreas—stomach cancer	0.0004	0.00511	CbGeAlD
Ponatinib—SRC—endocrine gland—stomach cancer	0.000397	0.00508	CbGeAlD
Ponatinib—KIT—lymphoid tissue—stomach cancer	0.000397	0.00508	CbGeAlD
Ponatinib—KIT—digestive system—stomach cancer	0.000392	0.00502	CbGeAlD
Ponatinib—FGFR1—lymph node—stomach cancer	0.000379	0.00485	CbGeAlD
Ponatinib—KDR—endocrine gland—stomach cancer	0.000366	0.00468	CbGeAlD
Ponatinib—PDGFRA—liver—stomach cancer	0.000365	0.00468	CbGeAlD
Ponatinib—KIT—bone marrow—stomach cancer	0.000361	0.00462	CbGeAlD
Ponatinib—SRC—liver—stomach cancer	0.000358	0.00458	CbGeAlD
Ponatinib—ABL1—lymphoid tissue—stomach cancer	0.000346	0.00442	CbGeAlD
Ponatinib—ABL1—digestive system—stomach cancer	0.000341	0.00437	CbGeAlD
Ponatinib—LCK—lymph node—stomach cancer	0.000339	0.00434	CbGeAlD
Ponatinib—RET—lymph node—stomach cancer	0.000339	0.00434	CbGeAlD
Ponatinib—KDR—liver—stomach cancer	0.00033	0.00422	CbGeAlD
Ponatinib—KIT—endocrine gland—stomach cancer	0.000324	0.00415	CbGeAlD
Ponatinib—CYP2C8—hematopoietic system—stomach cancer	0.000318	0.00407	CbGeAlD
Ponatinib—ABL1—bone marrow—stomach cancer	0.000315	0.00403	CbGeAlD
Ponatinib—TEK—lymph node—stomach cancer	0.000309	0.00396	CbGeAlD
Ponatinib—KIT—liver—stomach cancer	0.000292	0.00374	CbGeAlD
Ponatinib—CYP3A5—hematopoietic system—stomach cancer	0.000287	0.00368	CbGeAlD
Ponatinib—ABCB1—blood vessel—stomach cancer	0.000287	0.00367	CbGeAlD
Ponatinib—ABL1—endocrine gland—stomach cancer	0.000282	0.00361	CbGeAlD
Ponatinib—PDGFRA—lymph node—stomach cancer	0.00028	0.00358	CbGeAlD
Ponatinib—ABL1—Doxorubicin—Epirubicin—stomach cancer	0.000279	0.0997	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Epirubicin—stomach cancer	0.000279	0.0997	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Epirubicin—stomach cancer	0.000279	0.0997	CbGdCrCtD
Ponatinib—SRC—lymph node—stomach cancer	0.000275	0.00352	CbGeAlD
Ponatinib—ABL1—Idarubicin—Doxorubicin—stomach cancer	0.000258	0.0923	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—stomach cancer	0.000258	0.0923	CbGdCrCtD
Ponatinib—ABL1—Epirubicin—Doxorubicin—stomach cancer	0.000258	0.0923	CbGdCrCtD
Ponatinib—ABL1—liver—stomach cancer	0.000254	0.00325	CbGeAlD
Ponatinib—KDR—lymph node—stomach cancer	0.000253	0.00323	CbGeAlD
Ponatinib—CYP3A5—pancreas—stomach cancer	0.000234	0.00299	CbGeAlD
Ponatinib—KIT—lymph node—stomach cancer	0.000224	0.00287	CbGeAlD
Ponatinib—CYP3A4—hematopoietic system—stomach cancer	0.000216	0.00276	CbGeAlD
Ponatinib—CYP2D6—hematopoietic system—stomach cancer	0.000212	0.00271	CbGeAlD
Ponatinib—CYP3A5—digestive system—stomach cancer	0.0002	0.00256	CbGeAlD
Ponatinib—ABCG2—bone marrow—stomach cancer	0.000198	0.00254	CbGeAlD
Ponatinib—ABL1—lymph node—stomach cancer	0.000195	0.00249	CbGeAlD
Ponatinib—CYP2C8—endocrine gland—stomach cancer	0.000183	0.00234	CbGeAlD
Ponatinib—CYP3A5—endocrine gland—stomach cancer	0.000165	0.00211	CbGeAlD
Ponatinib—CYP2C8—liver—stomach cancer	0.000165	0.00211	CbGeAlD
Ponatinib—ABCG2—liver—stomach cancer	0.00016	0.00205	CbGeAlD
Ponatinib—ABCB1—hematopoietic system—stomach cancer	0.000153	0.00195	CbGeAlD
Ponatinib—CYP3A4—digestive system—stomach cancer	0.00015	0.00192	CbGeAlD
Ponatinib—CYP3A5—liver—stomach cancer	0.000149	0.0019	CbGeAlD
Ponatinib—CYP2D6—digestive system—stomach cancer	0.000148	0.00189	CbGeAlD
Ponatinib—ABCB1—epithelium—stomach cancer	0.00014	0.00179	CbGeAlD
Ponatinib—Imatinib—ALB—stomach cancer	0.000137	0.0318	CrCbGaD
Ponatinib—ABCB1—pancreas—stomach cancer	0.000124	0.00159	CbGeAlD
Ponatinib—CYP3A4—endocrine gland—stomach cancer	0.000124	0.00159	CbGeAlD
Ponatinib—ABCG2—lymph node—stomach cancer	0.000123	0.00157	CbGeAlD
Ponatinib—CYP2D6—endocrine gland—stomach cancer	0.000122	0.00156	CbGeAlD
Ponatinib—CYP3A4—liver—stomach cancer	0.000112	0.00143	CbGeAlD
Ponatinib—CYP2D6—liver—stomach cancer	0.00011	0.00141	CbGeAlD
Ponatinib—ABCB1—lymphoid tissue—stomach cancer	0.000107	0.00137	CbGeAlD
Ponatinib—ABCB1—digestive system—stomach cancer	0.000106	0.00136	CbGeAlD
Ponatinib—ABCB1—bone marrow—stomach cancer	9.78e-05	0.00125	CbGeAlD
Ponatinib—ABCB1—endocrine gland—stomach cancer	8.77e-05	0.00112	CbGeAlD
Ponatinib—ABCB1—liver—stomach cancer	7.91e-05	0.00101	CbGeAlD
Ponatinib—Urinary tract infection—Epirubicin—stomach cancer	7.52e-05	0.000576	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—stomach cancer	7.5e-05	0.000575	CcSEcCtD
Ponatinib—Hypertension—Capecitabine—stomach cancer	7.49e-05	0.000574	CcSEcCtD
Ponatinib—Dry mouth—Docetaxel—stomach cancer	7.46e-05	0.000572	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Doxorubicin—stomach cancer	7.46e-05	0.000571	CcSEcCtD
Ponatinib—Haemoglobin—Methotrexate—stomach cancer	7.46e-05	0.000571	CcSEcCtD
Ponatinib—Haemorrhage—Methotrexate—stomach cancer	7.42e-05	0.000568	CcSEcCtD
Ponatinib—Myalgia—Capecitabine—stomach cancer	7.39e-05	0.000566	CcSEcCtD
Ponatinib—Arthralgia—Capecitabine—stomach cancer	7.39e-05	0.000566	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	7.33e-05	0.000562	CcSEcCtD
Ponatinib—Hepatobiliary disease—Epirubicin—stomach cancer	7.31e-05	0.00056	CcSEcCtD
Ponatinib—Oedema—Docetaxel—stomach cancer	7.31e-05	0.00056	CcSEcCtD
Ponatinib—Epistaxis—Epirubicin—stomach cancer	7.29e-05	0.000559	CcSEcCtD
Ponatinib—Infection—Docetaxel—stomach cancer	7.26e-05	0.000557	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—stomach cancer	7.26e-05	0.000556	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—stomach cancer	7.24e-05	0.000555	CcSEcCtD
Ponatinib—Diarrhoea—Irinotecan—stomach cancer	7.24e-05	0.000555	CcSEcCtD
Ponatinib—Dry mouth—Capecitabine—stomach cancer	7.22e-05	0.000553	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—stomach cancer	7.2e-05	0.000551	CcSEcCtD
Ponatinib—Nervous system disorder—Docetaxel—stomach cancer	7.17e-05	0.000549	CcSEcCtD
Ponatinib—Pruritus—Fluorouracil—stomach cancer	7.17e-05	0.000549	CcSEcCtD
Ponatinib—Thrombocytopenia—Docetaxel—stomach cancer	7.16e-05	0.000549	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—stomach cancer	7.16e-05	0.000548	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—stomach cancer	7.16e-05	0.000548	CcSEcCtD
Ponatinib—Visual impairment—Methotrexate—stomach cancer	7.15e-05	0.000548	CcSEcCtD
Ponatinib—Skin disorder—Docetaxel—stomach cancer	7.1e-05	0.000544	CcSEcCtD
Ponatinib—Oedema—Capecitabine—stomach cancer	7.08e-05	0.000542	CcSEcCtD
Ponatinib—Infection—Capecitabine—stomach cancer	7.03e-05	0.000539	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—stomach cancer	7.01e-05	0.000537	CcSEcCtD
Ponatinib—Dizziness—Irinotecan—stomach cancer	7e-05	0.000536	CcSEcCtD
Ponatinib—Haemoglobin—Epirubicin—stomach cancer	6.98e-05	0.000535	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—stomach cancer	6.97e-05	0.000534	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—stomach cancer	6.97e-05	0.000534	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—stomach cancer	6.96e-05	0.000533	CcSEcCtD
Ponatinib—Nervous system disorder—Capecitabine—stomach cancer	6.94e-05	0.000532	CcSEcCtD
Ponatinib—Haemorrhage—Epirubicin—stomach cancer	6.94e-05	0.000532	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—stomach cancer	6.93e-05	0.000531	CcSEcCtD
Ponatinib—Diarrhoea—Fluorouracil—stomach cancer	6.93e-05	0.000531	CcSEcCtD
Ponatinib—Thrombocytopenia—Capecitabine—stomach cancer	6.93e-05	0.000531	CcSEcCtD
Ponatinib—Hypoaesthesia—Epirubicin—stomach cancer	6.91e-05	0.000529	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—stomach cancer	6.88e-05	0.000528	CcSEcCtD
Ponatinib—Skin disorder—Capecitabine—stomach cancer	6.88e-05	0.000527	CcSEcCtD
Ponatinib—Hyperhidrosis—Capecitabine—stomach cancer	6.84e-05	0.000524	CcSEcCtD
Ponatinib—Oedema peripheral—Epirubicin—stomach cancer	6.84e-05	0.000524	CcSEcCtD
Ponatinib—Connective tissue disorder—Epirubicin—stomach cancer	6.82e-05	0.000523	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—stomach cancer	6.77e-05	0.000519	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—stomach cancer	6.75e-05	0.000517	CcSEcCtD
Ponatinib—Angiopathy—Methotrexate—stomach cancer	6.73e-05	0.000516	CcSEcCtD
Ponatinib—Vomiting—Irinotecan—stomach cancer	6.73e-05	0.000515	CcSEcCtD
Ponatinib—Dizziness—Fluorouracil—stomach cancer	6.7e-05	0.000513	CcSEcCtD
Ponatinib—Visual impairment—Epirubicin—stomach cancer	6.69e-05	0.000513	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—stomach cancer	6.69e-05	0.000512	CcSEcCtD
Ponatinib—Rash—Irinotecan—stomach cancer	6.67e-05	0.000511	CcSEcCtD
Ponatinib—Dermatitis—Irinotecan—stomach cancer	6.66e-05	0.000511	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Docetaxel—stomach cancer	6.66e-05	0.00051	CcSEcCtD
Ponatinib—Chills—Methotrexate—stomach cancer	6.66e-05	0.00051	CcSEcCtD
Ponatinib—Headache—Irinotecan—stomach cancer	6.63e-05	0.000508	CcSEcCtD
Ponatinib—Insomnia—Docetaxel—stomach cancer	6.61e-05	0.000507	CcSEcCtD
Ponatinib—Paraesthesia—Docetaxel—stomach cancer	6.57e-05	0.000503	CcSEcCtD
Ponatinib—Alopecia—Methotrexate—stomach cancer	6.56e-05	0.000502	CcSEcCtD
Ponatinib—Dyspnoea—Docetaxel—stomach cancer	6.52e-05	0.0005	CcSEcCtD
Ponatinib—Mental disorder—Methotrexate—stomach cancer	6.5e-05	0.000498	CcSEcCtD
Ponatinib—Eye disorder—Epirubicin—stomach cancer	6.49e-05	0.000497	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—stomach cancer	6.46e-05	0.000495	CcSEcCtD
Ponatinib—Erythema—Methotrexate—stomach cancer	6.46e-05	0.000495	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—stomach cancer	6.46e-05	0.000495	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Capecitabine—stomach cancer	6.45e-05	0.000494	CcSEcCtD
Ponatinib—Cardiac disorder—Epirubicin—stomach cancer	6.44e-05	0.000494	CcSEcCtD
Ponatinib—Flushing—Epirubicin—stomach cancer	6.44e-05	0.000494	CcSEcCtD
Ponatinib—Vomiting—Fluorouracil—stomach cancer	6.44e-05	0.000494	CcSEcCtD
Ponatinib—Dyspepsia—Docetaxel—stomach cancer	6.44e-05	0.000493	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—stomach cancer	6.42e-05	0.000492	CcSEcCtD
Ponatinib—Insomnia—Capecitabine—stomach cancer	6.4e-05	0.000491	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—stomach cancer	6.39e-05	0.00049	CcSEcCtD
Ponatinib—Rash—Fluorouracil—stomach cancer	6.39e-05	0.000489	CcSEcCtD
Ponatinib—Dermatitis—Fluorouracil—stomach cancer	6.38e-05	0.000489	CcSEcCtD
Ponatinib—Paraesthesia—Capecitabine—stomach cancer	6.36e-05	0.000487	CcSEcCtD
Ponatinib—Decreased appetite—Docetaxel—stomach cancer	6.36e-05	0.000487	CcSEcCtD
Ponatinib—Headache—Fluorouracil—stomach cancer	6.35e-05	0.000486	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—stomach cancer	6.33e-05	0.000485	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Docetaxel—stomach cancer	6.31e-05	0.000484	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—stomach cancer	6.31e-05	0.000484	CcSEcCtD
Ponatinib—Dyspnoea—Capecitabine—stomach cancer	6.31e-05	0.000484	CcSEcCtD
Ponatinib—Fatigue—Docetaxel—stomach cancer	6.3e-05	0.000483	CcSEcCtD
Ponatinib—Angiopathy—Epirubicin—stomach cancer	6.3e-05	0.000483	CcSEcCtD
Ponatinib—Nausea—Irinotecan—stomach cancer	6.28e-05	0.000481	CcSEcCtD
Ponatinib—Mediastinal disorder—Epirubicin—stomach cancer	6.26e-05	0.000479	CcSEcCtD
Ponatinib—Pain—Docetaxel—stomach cancer	6.25e-05	0.000479	CcSEcCtD
Ponatinib—Constipation—Docetaxel—stomach cancer	6.25e-05	0.000479	CcSEcCtD
Ponatinib—Back pain—Methotrexate—stomach cancer	6.25e-05	0.000479	CcSEcCtD
Ponatinib—Dyspepsia—Capecitabine—stomach cancer	6.23e-05	0.000477	CcSEcCtD
Ponatinib—Chills—Epirubicin—stomach cancer	6.23e-05	0.000477	CcSEcCtD
Ponatinib—Arrhythmia—Epirubicin—stomach cancer	6.2e-05	0.000475	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—stomach cancer	6.19e-05	0.000474	CcSEcCtD
Ponatinib—Decreased appetite—Capecitabine—stomach cancer	6.15e-05	0.000472	CcSEcCtD
Ponatinib—Alopecia—Epirubicin—stomach cancer	6.13e-05	0.00047	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Capecitabine—stomach cancer	6.11e-05	0.000468	CcSEcCtD
Ponatinib—Fatigue—Capecitabine—stomach cancer	6.1e-05	0.000468	CcSEcCtD
Ponatinib—Vision blurred—Methotrexate—stomach cancer	6.09e-05	0.000466	CcSEcCtD
Ponatinib—Mental disorder—Epirubicin—stomach cancer	6.08e-05	0.000466	CcSEcCtD
Ponatinib—ABCB1—lymph node—stomach cancer	6.06e-05	0.000776	CbGeAlD
Ponatinib—Constipation—Capecitabine—stomach cancer	6.05e-05	0.000464	CcSEcCtD
Ponatinib—Pain—Capecitabine—stomach cancer	6.05e-05	0.000464	CcSEcCtD
Ponatinib—Malnutrition—Epirubicin—stomach cancer	6.04e-05	0.000463	CcSEcCtD
Ponatinib—Erythema—Epirubicin—stomach cancer	6.04e-05	0.000463	CcSEcCtD
Ponatinib—Nausea—Fluorouracil—stomach cancer	6.02e-05	0.000461	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—stomach cancer	6e-05	0.00046	CcSEcCtD
Ponatinib—Gastrointestinal pain—Docetaxel—stomach cancer	5.98e-05	0.000458	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—stomach cancer	5.97e-05	0.000457	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—stomach cancer	5.96e-05	0.000457	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—stomach cancer	5.96e-05	0.000457	CcSEcCtD
Ponatinib—Back pain—Epirubicin—stomach cancer	5.85e-05	0.000448	CcSEcCtD
Ponatinib—Angiopathy—Doxorubicin—stomach cancer	5.83e-05	0.000447	CcSEcCtD
Ponatinib—Muscle spasms—Epirubicin—stomach cancer	5.81e-05	0.000445	CcSEcCtD
Ponatinib—Gastrointestinal pain—Capecitabine—stomach cancer	5.79e-05	0.000444	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—stomach cancer	5.79e-05	0.000444	CcSEcCtD
Ponatinib—Abdominal pain—Docetaxel—stomach cancer	5.78e-05	0.000443	CcSEcCtD
Ponatinib—Body temperature increased—Docetaxel—stomach cancer	5.78e-05	0.000443	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—stomach cancer	5.78e-05	0.000443	CcSEcCtD
Ponatinib—Chills—Doxorubicin—stomach cancer	5.76e-05	0.000442	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—stomach cancer	5.74e-05	0.00044	CcSEcCtD
Ponatinib—Vision blurred—Epirubicin—stomach cancer	5.7e-05	0.000436	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—stomach cancer	5.68e-05	0.000435	CcSEcCtD
Ponatinib—Cough—Methotrexate—stomach cancer	5.64e-05	0.000432	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—stomach cancer	5.63e-05	0.000431	CcSEcCtD
Ponatinib—Abdominal pain—Capecitabine—stomach cancer	5.6e-05	0.000429	CcSEcCtD
Ponatinib—Body temperature increased—Capecitabine—stomach cancer	5.6e-05	0.000429	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—stomach cancer	5.59e-05	0.000428	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—stomach cancer	5.59e-05	0.000428	CcSEcCtD
Ponatinib—Anaemia—Epirubicin—stomach cancer	5.59e-05	0.000428	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—stomach cancer	5.5e-05	0.000421	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—stomach cancer	5.5e-05	0.000421	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	5.46e-05	0.000418	CcSEcCtD
Ponatinib—Leukopenia—Epirubicin—stomach cancer	5.41e-05	0.000414	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—stomach cancer	5.41e-05	0.000414	CcSEcCtD
Ponatinib—Muscle spasms—Doxorubicin—stomach cancer	5.38e-05	0.000412	CcSEcCtD
Ponatinib—Cough—Epirubicin—stomach cancer	5.27e-05	0.000404	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—stomach cancer	5.27e-05	0.000404	CcSEcCtD
Ponatinib—Asthenia—Docetaxel—stomach cancer	5.25e-05	0.000402	CcSEcCtD
Ponatinib—Infection—Methotrexate—stomach cancer	5.24e-05	0.000401	CcSEcCtD
Ponatinib—Hypertension—Epirubicin—stomach cancer	5.22e-05	0.0004	CcSEcCtD
Ponatinib—Pruritus—Docetaxel—stomach cancer	5.17e-05	0.000396	CcSEcCtD
Ponatinib—Nervous system disorder—Methotrexate—stomach cancer	5.17e-05	0.000396	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—stomach cancer	5.17e-05	0.000396	CcSEcCtD
Ponatinib—Thrombocytopenia—Methotrexate—stomach cancer	5.16e-05	0.000395	CcSEcCtD
Ponatinib—Arthralgia—Epirubicin—stomach cancer	5.15e-05	0.000394	CcSEcCtD
Ponatinib—Myalgia—Epirubicin—stomach cancer	5.15e-05	0.000394	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—stomach cancer	5.12e-05	0.000392	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	5.11e-05	0.000391	CcSEcCtD
Ponatinib—Hyperhidrosis—Methotrexate—stomach cancer	5.1e-05	0.00039	CcSEcCtD
Ponatinib—Asthenia—Capecitabine—stomach cancer	5.08e-05	0.000389	CcSEcCtD
Ponatinib—Dry mouth—Epirubicin—stomach cancer	5.03e-05	0.000386	CcSEcCtD
Ponatinib—Pruritus—Capecitabine—stomach cancer	5.01e-05	0.000384	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—stomach cancer	5.01e-05	0.000384	CcSEcCtD
Ponatinib—Diarrhoea—Docetaxel—stomach cancer	5e-05	0.000383	CcSEcCtD
Ponatinib—Oedema—Epirubicin—stomach cancer	4.93e-05	0.000378	CcSEcCtD
Ponatinib—Infection—Epirubicin—stomach cancer	4.9e-05	0.000375	CcSEcCtD
Ponatinib—Cough—Doxorubicin—stomach cancer	4.88e-05	0.000374	CcSEcCtD
Ponatinib—Diarrhoea—Capecitabine—stomach cancer	4.84e-05	0.000371	CcSEcCtD
Ponatinib—Nervous system disorder—Epirubicin—stomach cancer	4.84e-05	0.000371	CcSEcCtD
Ponatinib—Dizziness—Docetaxel—stomach cancer	4.84e-05	0.00037	CcSEcCtD
Ponatinib—Thrombocytopenia—Epirubicin—stomach cancer	4.83e-05	0.00037	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—stomach cancer	4.83e-05	0.00037	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methotrexate—stomach cancer	4.8e-05	0.000368	CcSEcCtD
Ponatinib—Skin disorder—Epirubicin—stomach cancer	4.79e-05	0.000367	CcSEcCtD
Ponatinib—Hyperhidrosis—Epirubicin—stomach cancer	4.77e-05	0.000365	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—stomach cancer	4.77e-05	0.000365	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—stomach cancer	4.76e-05	0.000365	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—stomach cancer	4.76e-05	0.000365	CcSEcCtD
Ponatinib—Paraesthesia—Methotrexate—stomach cancer	4.73e-05	0.000363	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	4.73e-05	0.000362	CcSEcCtD
Ponatinib—Dyspnoea—Methotrexate—stomach cancer	4.7e-05	0.00036	CcSEcCtD
Ponatinib—Dizziness—Capecitabine—stomach cancer	4.68e-05	0.000359	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—stomach cancer	4.66e-05	0.000357	CcSEcCtD
Ponatinib—Vomiting—Docetaxel—stomach cancer	4.65e-05	0.000356	CcSEcCtD
Ponatinib—Dyspepsia—Methotrexate—stomach cancer	4.64e-05	0.000355	CcSEcCtD
Ponatinib—Rash—Docetaxel—stomach cancer	4.61e-05	0.000353	CcSEcCtD
Ponatinib—Dermatitis—Docetaxel—stomach cancer	4.61e-05	0.000353	CcSEcCtD
Ponatinib—Decreased appetite—Methotrexate—stomach cancer	4.58e-05	0.000351	CcSEcCtD
Ponatinib—Headache—Docetaxel—stomach cancer	4.58e-05	0.000351	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—stomach cancer	4.56e-05	0.00035	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Methotrexate—stomach cancer	4.55e-05	0.000349	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—stomach cancer	4.54e-05	0.000348	CcSEcCtD
Ponatinib—Infection—Doxorubicin—stomach cancer	4.53e-05	0.000347	CcSEcCtD
Ponatinib—Pain—Methotrexate—stomach cancer	4.51e-05	0.000345	CcSEcCtD
Ponatinib—Vomiting—Capecitabine—stomach cancer	4.5e-05	0.000345	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Epirubicin—stomach cancer	4.49e-05	0.000344	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—stomach cancer	4.48e-05	0.000343	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—stomach cancer	4.47e-05	0.000342	CcSEcCtD
Ponatinib—Rash—Capecitabine—stomach cancer	4.46e-05	0.000342	CcSEcCtD
Ponatinib—Insomnia—Epirubicin—stomach cancer	4.46e-05	0.000342	CcSEcCtD
Ponatinib—Dermatitis—Capecitabine—stomach cancer	4.46e-05	0.000342	CcSEcCtD
Ponatinib—Headache—Capecitabine—stomach cancer	4.44e-05	0.00034	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—stomach cancer	4.43e-05	0.00034	CcSEcCtD
Ponatinib—Paraesthesia—Epirubicin—stomach cancer	4.43e-05	0.000339	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—stomach cancer	4.41e-05	0.000338	CcSEcCtD
Ponatinib—Dyspnoea—Epirubicin—stomach cancer	4.4e-05	0.000337	CcSEcCtD
Ponatinib—Nausea—Docetaxel—stomach cancer	4.34e-05	0.000333	CcSEcCtD
Ponatinib—Dyspepsia—Epirubicin—stomach cancer	4.34e-05	0.000333	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methotrexate—stomach cancer	4.31e-05	0.00033	CcSEcCtD
Ponatinib—Decreased appetite—Epirubicin—stomach cancer	4.29e-05	0.000329	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Epirubicin—stomach cancer	4.26e-05	0.000326	CcSEcCtD
Ponatinib—Fatigue—Epirubicin—stomach cancer	4.25e-05	0.000326	CcSEcCtD
Ponatinib—Pain—Epirubicin—stomach cancer	4.22e-05	0.000323	CcSEcCtD
Ponatinib—Constipation—Epirubicin—stomach cancer	4.22e-05	0.000323	CcSEcCtD
Ponatinib—Nausea—Capecitabine—stomach cancer	4.21e-05	0.000322	CcSEcCtD
Ponatinib—Body temperature increased—Methotrexate—stomach cancer	4.17e-05	0.000319	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—stomach cancer	4.17e-05	0.000319	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—stomach cancer	4.16e-05	0.000319	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—stomach cancer	4.13e-05	0.000316	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—stomach cancer	4.1e-05	0.000314	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—stomach cancer	4.07e-05	0.000312	CcSEcCtD
Ponatinib—Gastrointestinal pain—Epirubicin—stomach cancer	4.03e-05	0.000309	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—stomach cancer	4.02e-05	0.000308	CcSEcCtD
Ponatinib—Decreased appetite—Doxorubicin—stomach cancer	3.97e-05	0.000304	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—stomach cancer	3.94e-05	0.000302	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—stomach cancer	3.93e-05	0.000301	CcSEcCtD
Ponatinib—Pain—Doxorubicin—stomach cancer	3.9e-05	0.000299	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—stomach cancer	3.9e-05	0.000299	CcSEcCtD
Ponatinib—Abdominal pain—Epirubicin—stomach cancer	3.9e-05	0.000299	CcSEcCtD
Ponatinib—Body temperature increased—Epirubicin—stomach cancer	3.9e-05	0.000299	CcSEcCtD
Ponatinib—Asthenia—Methotrexate—stomach cancer	3.78e-05	0.00029	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—stomach cancer	3.73e-05	0.000286	CcSEcCtD
Ponatinib—Pruritus—Methotrexate—stomach cancer	3.73e-05	0.000286	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—stomach cancer	3.61e-05	0.000276	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—stomach cancer	3.61e-05	0.000276	CcSEcCtD
Ponatinib—Diarrhoea—Methotrexate—stomach cancer	3.61e-05	0.000276	CcSEcCtD
Ponatinib—Asthenia—Epirubicin—stomach cancer	3.54e-05	0.000271	CcSEcCtD
Ponatinib—Pruritus—Epirubicin—stomach cancer	3.49e-05	0.000267	CcSEcCtD
Ponatinib—Dizziness—Methotrexate—stomach cancer	3.49e-05	0.000267	CcSEcCtD
Ponatinib—Diarrhoea—Epirubicin—stomach cancer	3.37e-05	0.000259	CcSEcCtD
Ponatinib—Vomiting—Methotrexate—stomach cancer	3.35e-05	0.000257	CcSEcCtD
Ponatinib—Rash—Methotrexate—stomach cancer	3.32e-05	0.000255	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—stomach cancer	3.32e-05	0.000254	CcSEcCtD
Ponatinib—Headache—Methotrexate—stomach cancer	3.3e-05	0.000253	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—stomach cancer	3.27e-05	0.000251	CcSEcCtD
Ponatinib—Dizziness—Epirubicin—stomach cancer	3.26e-05	0.00025	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—stomach cancer	3.23e-05	0.000247	CcSEcCtD
Ponatinib—Vomiting—Epirubicin—stomach cancer	3.14e-05	0.00024	CcSEcCtD
Ponatinib—Nausea—Methotrexate—stomach cancer	3.13e-05	0.00024	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—stomach cancer	3.12e-05	0.000239	CcSEcCtD
Ponatinib—Rash—Epirubicin—stomach cancer	3.11e-05	0.000238	CcSEcCtD
Ponatinib—Dermatitis—Epirubicin—stomach cancer	3.11e-05	0.000238	CcSEcCtD
Ponatinib—Headache—Epirubicin—stomach cancer	3.09e-05	0.000237	CcSEcCtD
Ponatinib—Dizziness—Doxorubicin—stomach cancer	3.02e-05	0.000231	CcSEcCtD
Ponatinib—Nausea—Epirubicin—stomach cancer	2.93e-05	0.000224	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—stomach cancer	2.9e-05	0.000222	CcSEcCtD
Ponatinib—Rash—Doxorubicin—stomach cancer	2.88e-05	0.00022	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—stomach cancer	2.87e-05	0.00022	CcSEcCtD
Ponatinib—Headache—Doxorubicin—stomach cancer	2.86e-05	0.000219	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—stomach cancer	2.71e-05	0.000208	CcSEcCtD
Ponatinib—ABCB1—Metabolism—PPP2R1A—stomach cancer	1.45e-06	8.89e-06	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HRAS—stomach cancer	1.45e-06	8.88e-06	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL6—stomach cancer	1.45e-06	8.88e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6R—stomach cancer	1.44e-06	8.82e-06	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HRAS—stomach cancer	1.43e-06	8.81e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PRKCB—stomach cancer	1.43e-06	8.79e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PIK3CA—stomach cancer	1.43e-06	8.79e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HRAS—stomach cancer	1.43e-06	8.78e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—stomach cancer	1.43e-06	8.78e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—DPYD—stomach cancer	1.43e-06	8.77e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PIK3CA—stomach cancer	1.43e-06	8.77e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6ST—stomach cancer	1.43e-06	8.75e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—stomach cancer	1.42e-06	8.75e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CDKN1A—stomach cancer	1.42e-06	8.74e-06	CbGpPWpGaD
Ponatinib—FGFR2—Disease—HRAS—stomach cancer	1.42e-06	8.72e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTP1—stomach cancer	1.42e-06	8.72e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CDKN1A—stomach cancer	1.42e-06	8.72e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—STAT3—stomach cancer	1.42e-06	8.7e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CAV1—stomach cancer	1.41e-06	8.66e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ERCC2—stomach cancer	1.41e-06	8.65e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APOA1—stomach cancer	1.41e-06	8.64e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—CDKN1B—stomach cancer	1.41e-06	8.64e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—CDKN1A—stomach cancer	1.41e-06	8.63e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—HMOX1—stomach cancer	1.4e-06	8.6e-06	CbGpPWpGaD
Ponatinib—KIT—Disease—HRAS—stomach cancer	1.39e-06	8.57e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCL8—stomach cancer	1.39e-06	8.54e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK8—stomach cancer	1.39e-06	8.53e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK8—stomach cancer	1.39e-06	8.51e-06	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL6—stomach cancer	1.38e-06	8.5e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—stomach cancer	1.38e-06	8.45e-06	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—stomach cancer	1.37e-06	8.43e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK8—stomach cancer	1.37e-06	8.43e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APC—stomach cancer	1.37e-06	8.41e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—stomach cancer	1.37e-06	8.41e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPP2R1A—stomach cancer	1.36e-06	8.38e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—PIK3CA—stomach cancer	1.36e-06	8.37e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—STAT3—stomach cancer	1.36e-06	8.37e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PIK3CA—stomach cancer	1.36e-06	8.36e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—stomach cancer	1.36e-06	8.36e-06	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—stomach cancer	1.36e-06	8.35e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—PIK3CA—stomach cancer	1.36e-06	8.34e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1B—stomach cancer	1.36e-06	8.34e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK3—stomach cancer	1.35e-06	8.31e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—stomach cancer	1.35e-06	8.3e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SERPINE1—stomach cancer	1.34e-06	8.26e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—STAT3—stomach cancer	1.34e-06	8.22e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTP1—stomach cancer	1.34e-06	8.22e-06	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—stomach cancer	1.33e-06	8.2e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—stomach cancer	1.32e-06	8.13e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MTHFR—stomach cancer	1.32e-06	8.13e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—stomach cancer	1.32e-06	8.11e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TYMS—stomach cancer	1.32e-06	8.11e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—HMOX1—stomach cancer	1.32e-06	8.11e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—stomach cancer	1.32e-06	8.09e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—STAT3—stomach cancer	1.31e-06	8.03e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTM1—stomach cancer	1.3e-06	8.01e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK3—stomach cancer	1.3e-06	8e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—CDKN1A—stomach cancer	1.3e-06	7.97e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RHOA—stomach cancer	1.3e-06	7.97e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCND1—stomach cancer	1.29e-06	7.95e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—JUN—stomach cancer	1.29e-06	7.94e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK1—stomach cancer	1.29e-06	7.91e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—stomach cancer	1.29e-06	7.91e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NOS3—stomach cancer	1.28e-06	7.89e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—stomach cancer	1.28e-06	7.88e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—stomach cancer	1.28e-06	7.86e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK3—stomach cancer	1.28e-06	7.85e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6R—stomach cancer	1.27e-06	7.81e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—STAT3—stomach cancer	1.27e-06	7.8e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—stomach cancer	1.27e-06	7.78e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—STAT3—stomach cancer	1.27e-06	7.78e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CA—stomach cancer	1.27e-06	7.78e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—stomach cancer	1.27e-06	7.78e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—stomach cancer	1.26e-06	7.76e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTT1—stomach cancer	1.26e-06	7.75e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—stomach cancer	1.26e-06	7.75e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—stomach cancer	1.26e-06	7.74e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—stomach cancer	1.26e-06	7.72e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—stomach cancer	1.26e-06	7.71e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—STAT3—stomach cancer	1.25e-06	7.7e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1A—stomach cancer	1.25e-06	7.69e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK3—stomach cancer	1.25e-06	7.68e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2A6—stomach cancer	1.25e-06	7.66e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TYMS—stomach cancer	1.24e-06	7.64e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—stomach cancer	1.24e-06	7.64e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARG—stomach cancer	1.24e-06	7.61e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK1—stomach cancer	1.24e-06	7.61e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—stomach cancer	1.24e-06	7.61e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTM1—stomach cancer	1.23e-06	7.55e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ERCC2—stomach cancer	1.23e-06	7.54e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK8—stomach cancer	1.22e-06	7.51e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CAV1—stomach cancer	1.22e-06	7.5e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOA1—stomach cancer	1.22e-06	7.48e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK1—stomach cancer	1.22e-06	7.47e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—stomach cancer	1.22e-06	7.47e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—stomach cancer	1.22e-06	7.47e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—stomach cancer	1.22e-06	7.47e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKR1C3—stomach cancer	1.21e-06	7.45e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK3—stomach cancer	1.21e-06	7.45e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK3—stomach cancer	1.21e-06	7.43e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—stomach cancer	1.21e-06	7.42e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—stomach cancer	1.21e-06	7.41e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—stomach cancer	1.2e-06	7.38e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB2—stomach cancer	1.2e-06	7.38e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK3—stomach cancer	1.2e-06	7.36e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SERPINE1—stomach cancer	1.19e-06	7.31e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK1—stomach cancer	1.19e-06	7.3e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—stomach cancer	1.19e-06	7.3e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ENO1—stomach cancer	1.18e-06	7.26e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—stomach cancer	1.18e-06	7.25e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—stomach cancer	1.18e-06	7.23e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—stomach cancer	1.17e-06	7.19e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	1.17e-06	7.16e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—STAT3—stomach cancer	1.16e-06	7.11e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ERCC2—stomach cancer	1.16e-06	7.1e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK1—stomach cancer	1.15e-06	7.09e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—stomach cancer	1.15e-06	7.09e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MTHFR—stomach cancer	1.15e-06	7.08e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK1—stomach cancer	1.15e-06	7.07e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—stomach cancer	1.15e-06	7.07e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—stomach cancer	1.15e-06	7.06e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RHOA—stomach cancer	1.15e-06	7.05e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK1—stomach cancer	1.14e-06	7e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—stomach cancer	1.14e-06	7e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—stomach cancer	1.14e-06	7e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOS3—stomach cancer	1.14e-06	6.98e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—stomach cancer	1.13e-06	6.93e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—stomach cancer	1.12e-06	6.9e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—stomach cancer	1.12e-06	6.86e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STAT3—stomach cancer	1.12e-06	6.86e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ALB—stomach cancer	1.11e-06	6.84e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1B—stomach cancer	1.11e-06	6.83e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK3—stomach cancer	1.11e-06	6.8e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—stomach cancer	1.09e-06	6.7e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—stomach cancer	1.09e-06	6.68e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MTHFR—stomach cancer	1.09e-06	6.67e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—stomach cancer	1.08e-06	6.61e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—stomach cancer	1.08e-06	6.61e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—stomach cancer	1.07e-06	6.6e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARG—stomach cancer	1.07e-06	6.59e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK3—stomach cancer	1.07e-06	6.56e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—NOS3—stomach cancer	1.07e-06	6.55e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CAV1—stomach cancer	1.06e-06	6.53e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB2—stomach cancer	1.06e-06	6.53e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOA1—stomach cancer	1.06e-06	6.52e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—stomach cancer	1.06e-06	6.52e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—JUN—stomach cancer	1.06e-06	6.5e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—stomach cancer	1.06e-06	6.48e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK1—stomach cancer	1.05e-06	6.47e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—stomach cancer	1.05e-06	6.46e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CD44—stomach cancer	1.05e-06	6.44e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—stomach cancer	1.04e-06	6.39e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—stomach cancer	1.04e-06	6.38e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—stomach cancer	1.03e-06	6.35e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—stomach cancer	1.03e-06	6.34e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—stomach cancer	1.03e-06	6.33e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1A—stomach cancer	1.03e-06	6.31e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—stomach cancer	1.02e-06	6.27e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK1—stomach cancer	1.02e-06	6.24e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—stomach cancer	1.02e-06	6.24e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—stomach cancer	1.01e-06	6.19e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CAV1—stomach cancer	1e-06	6.16e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—stomach cancer	1e-06	6.15e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK8—stomach cancer	1e-06	6.15e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOA1—stomach cancer	1e-06	6.14e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—stomach cancer	9.99e-07	6.14e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—stomach cancer	9.94e-07	6.11e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—stomach cancer	9.94e-07	6.11e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—stomach cancer	9.89e-07	6.08e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—stomach cancer	9.89e-07	6.08e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1B—stomach cancer	9.85e-07	6.05e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—stomach cancer	9.77e-07	6e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—stomach cancer	9.75e-07	5.99e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—stomach cancer	9.69e-07	5.95e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—stomach cancer	9.67e-07	5.94e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ALB—stomach cancer	9.65e-07	5.93e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—stomach cancer	9.59e-07	5.89e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—stomach cancer	9.54e-07	5.86e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—stomach cancer	9.52e-07	5.85e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—stomach cancer	9.39e-07	5.77e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—JUN—stomach cancer	9.37e-07	5.76e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARG—stomach cancer	9.35e-07	5.74e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—stomach cancer	9.35e-07	5.74e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—stomach cancer	9.27e-07	5.69e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—stomach cancer	9.25e-07	5.68e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—stomach cancer	9.25e-07	5.68e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NOS3—stomach cancer	9.23e-07	5.67e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STAT3—stomach cancer	9.16e-07	5.63e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—stomach cancer	9.15e-07	5.62e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—stomach cancer	9.14e-07	5.61e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—stomach cancer	9.13e-07	5.61e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—stomach cancer	9.12e-07	5.6e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1A—stomach cancer	9.09e-07	5.58e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPP2R1A—stomach cancer	8.92e-07	5.48e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—stomach cancer	8.87e-07	5.45e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK8—stomach cancer	8.87e-07	5.45e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—stomach cancer	8.85e-07	5.44e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—stomach cancer	8.81e-07	5.41e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARG—stomach cancer	8.81e-07	5.41e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—stomach cancer	8.76e-07	5.38e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK3—stomach cancer	8.75e-07	5.38e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTP1—stomach cancer	8.75e-07	5.37e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HMOX1—stomach cancer	8.63e-07	5.3e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—stomach cancer	8.53e-07	5.24e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—stomach cancer	8.51e-07	5.23e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—stomach cancer	8.45e-07	5.19e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—stomach cancer	8.44e-07	5.19e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ALB—stomach cancer	8.41e-07	5.16e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—stomach cancer	8.37e-07	5.14e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK1—stomach cancer	8.33e-07	5.11e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—stomach cancer	8.32e-07	5.11e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—stomach cancer	8.19e-07	5.03e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—stomach cancer	8.15e-07	5.01e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TYMS—stomach cancer	8.13e-07	5e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT3—stomach cancer	8.11e-07	4.98e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—stomach cancer	8.09e-07	4.97e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NOS3—stomach cancer	8.04e-07	4.94e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTM1—stomach cancer	8.04e-07	4.94e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ALB—stomach cancer	7.92e-07	4.87e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—stomach cancer	7.86e-07	4.83e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—stomach cancer	7.8e-07	4.79e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK3—stomach cancer	7.75e-07	4.76e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NOS3—stomach cancer	7.58e-07	4.66e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ERCC2—stomach cancer	7.56e-07	4.64e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—stomach cancer	7.53e-07	4.63e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK1—stomach cancer	7.37e-07	4.53e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—stomach cancer	7.37e-07	4.53e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—stomach cancer	7.36e-07	4.52e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—stomach cancer	7.22e-07	4.44e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTHFR—stomach cancer	7.1e-07	4.36e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—stomach cancer	6.99e-07	4.29e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—stomach cancer	6.96e-07	4.28e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—stomach cancer	6.93e-07	4.26e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—stomach cancer	6.68e-07	4.11e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CAV1—stomach cancer	6.55e-07	4.03e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOA1—stomach cancer	6.54e-07	4.02e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—stomach cancer	6.4e-07	3.93e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—stomach cancer	6.4e-07	3.93e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—stomach cancer	6.19e-07	3.8e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—stomach cancer	6e-07	3.68e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—stomach cancer	5.92e-07	3.64e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARG—stomach cancer	5.76e-07	3.54e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—stomach cancer	5.66e-07	3.48e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—stomach cancer	5.19e-07	3.19e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALB—stomach cancer	5.18e-07	3.18e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NOS3—stomach cancer	4.95e-07	3.04e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—stomach cancer	4.53e-07	2.78e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—stomach cancer	4.53e-07	2.78e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—stomach cancer	4.26e-07	2.62e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—stomach cancer	2.79e-07	1.71e-06	CbGpPWpGaD
